Small circle of awareness Look for a big breakout on this stock as new investors become aware of how undervalued this company is. All the IP (91 patents) and data is worth multiples of the current valuation. The company has wisely dilutely all outsiders from having any serious percentage ownership. 369 million shares have turned over in the last 2 months of trading. The 20:1 rollback is strategic and will tighten up the liquidity whilst at the same time making it easier for the stock to move up hopefully in dramatic fashion . There are some big potential catalysts including the biggie: Hemostemix has entered into a contract with a new clinical research organization which is completing the midpoint statistical analyses of the efficacy of ACP-01.
The risk/reward here is massive. The current valuation is not reflective of the opportunity and I expect this will change in a big way over the next couple of months.